GlassScriptPhysician profile
Miriam L Freimer
NPI 1659455863
$104,872.44
in general payments reported to CMS, 2019-2025
18 companies · $7,012 in 2025
The $7,012 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,394 · 2020: $2,040 · 2021: $13K · 2022: $6,878 · 2023: $33K · 2024: $40K · 2025: $7,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $75K · Travel and Lodging: $2,993 · Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $75,407.00 |
| Travel and Lodging | $2,992.96 |
| Food and Beverage | $1,936.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $54,976.94 | 2021-2025 | Zilbrysq |
| Argenx US, INC. | $22,622.88 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $10,735.00 | 2020-2023 | Ultomiris |
| Ucb Sa | $10,643.62 | 2019-2024 | Rystiggo |
| Janssen Scientific Affairs, LLC | $2,323.76 | 2023-2024 | |
| Csl Behring | $1,950.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,600.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.24 | 2021 |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Freimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.